SIGAL ELLIOT 4
4 · Spark Therapeutics, Inc. · Filed Apr 16, 2018
Insider Transaction Report
Form 4
SIGAL ELLIOT
Director
Transactions
- Purchase
Common Stock
2017-10-12$90.75/sh+29$2,632→ 11,243 total - Sale
Common Stock
2017-11-28$72.43/sh−29$2,100→ 11,214 total
Footnotes (1)
- [F1]Reflects transactions occurring in a brokerage account managed by an investment advisor who maintained discretionary authority over the account. The transactions were made by the investment advisor in contradiction of the Reporting Person's instructions and without the Reporting Person's approval.